MicroRNA在乳腺癌耐药中的功能研究进展

Abstract
Figure/Table
References (33)
Related Citation (15)

Download: PDF (603 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Breast cancer is one of the most common malignant tumors in women, which is a serious threat to human health. In recent years, relying on the continuous improvement of early diagnosis and treatment strategies, breast cancer mortality has been declining year by year. However, drug resistance and relapse are the main obstacles to the treatment of breast cancer. The drug resistance of breast cancer is regulated by a variety of mechanisms, among which microRNAs (miRNA) may play an important role in all aspects of cancer progression. miRNAs are endogenous non-coding RNAs involved in the regulation of various biology processes, including cell proliferation, invasion, metastasis and drug resistance. Abnormal expression of specific miRNA can affect the expression of cell-associated proteins, the binding of anti-tumor drugs to targets and apoptosis-related pathways, leading to drug resistance. This paper reviews the studies on functional miRNAs involved in breast cancer drug resistance and their targets and related mechanisms, believing that miRNA can become be a biomarker and a new therapeutic target for clinical diagnosis and treatment of breast cancer.

Key words： Breast cancer MicroRNA Drug resistance

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HAO Shuai ZHAO Jianjie ZHANG Xiaohua TIAN Wuguo LUO Donglin

Cite this article:

HAO Shuai ZHAO Jianjie ZHANG Xiaohua TIAN Wuguo LUO Donglin. Advances in the function reserch of MicroRNA in breast cancer drug resistance[J]. 中国医药导报, 2020, 17(2): 29-32.

URL:

http://www.yiyaodaobao.com.cn/EN/ OR http://www.yiyaodaobao.com.cn/EN/Y2020/V17/I2/29

[1] Siegel RL，Miller KD，Jemal A. Cancer statistics，2018 [J]. CA Cancer J Clin，2018，68（1）：7-30.
[2] DeSantis C，Ma J，Bryan L，et al. Breast cancer statistics，2013 [J]. CA Cancer J Clin，2014，64（1）：52-62.
[3] Ellis LM，Hicklin DJ. Resistance to targeted therapies：refning anticancer therapy in the era of molecular oncology [J]. Clin Cancer Res，2009，15（24）：7471-7478.
[4] Sledge GW，Mamounas EP，Hortobagyi GN，et al. Past，present，and future challenges in breast cancer treatment [J]. J Clin Oncol，2014，32（19）：1979-1986.
[5] Hu W，Tan C，He Y，et al. Functional miRNAs in breast cancer drug resistance [J]. Onco Targets Ter，2018，11：1529-1541.
[6] Khordadmehr M，Shahbazi R，Ezzati H，et al. Key microRNAs in the biology of breast cancer；emerging evidence in the last decade [J]. J Cell Physiol，2019，234（6）：8316-8326.
[7] Mulrane L，Mcgee SF，Gallagher WM，et al. miRNA dysregulation in breast cancer [J]. Cancer Res，2013，73（22）：6554-6562.
[8] Lei HX，Wang XF，Wu C. Early stage intercalation of doxorubicin to DNA fragments observed in molecular dynamics binding simulations [J]. J Mol Graph Model，2012，38：279-289.
[9] Zeng H，Wang L，Wang J，et al. microRNA-129-5p suppresses Adriamycin resistance in breast cancer by targeting SOX2 [J]. Arch Biochem Biophys，2018，651：52-60.
[10] Li D，Wang X，Yang M，et al. miR3609 sensitizes breast cancer cells to adriamycin by blocking the programmed death-ligand 1 immune checkpoint [J]. Exp Cell Res，2019，380（1）：20-28.
[11] Chen X，Wang YW，Gao P. SPIN1，negatively regulated by miR-148/152，enhances Adriamycin resistance via upregulating drug metabolizing enzymes and transporter in breast cancer [J]. J Exp Clin Cancer Res，2018，37（1）：100.
[12] Tormo E，Ballester S，Adam-Artigues A，et al. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors [J]. Sci Rep，2019，9（1）：5316.
[13] Cheung HW，Jin DY，Ling MT，et al. Mitotic arrest deficient 2 expression induces chemosensitization to a DNA-damaging agent，cisplatin，in nasopharyngeal carcinoma cells [J]. Cancer Res，2005，65（4）：1450-1458.
[14] Wang X，Zhu J. Mir-1307 regulates cisplatin resistance by targeting Mdm4 in breast cancer expressing wild type P53 [J]. Thorac Cancer，2018，9（6）：676-683.
[15] Cataldo A，Cheung DG，Balsari A，et al. miR-302b enhances breast cancer cell sensitivity to cisplatin by regulating E2F1 and the cellular DNA damage response [J]. Oncotarget，2016，7（1）：786-797.
[16] Wu MY，Fu J，Xiao X，et al. MiR-34a regulates therapy resistance by targeting HDAC1 and HDAC7 in breast cancer [J]. Cancer Lett，2014，354（2）：311-9.
[17] Zhang Y，Wang Y，Wei Y，et al. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition [J]. Sci Rep，2015，5：15424.
[18] Xiang F，Fan Y，Ni Z，et al. Ursolic Acid Reverses the Chemoresistance of Breast Cancer Cells to Paclitaxel by Targeting MiRNA-149-5p/MyD88 [J]. Front Oncol，2019，9：501.
[19] Lyu H，Wang SL，Huang JC，et al. Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer [J]. Cancer Lett，2018，420：97-108.
[20] Howard EW，Yang X. MicroRNA regulation in estrogen receptor-positive breast cancer and endocrine therapy [J]. Biol Proced Online，2018，20：17.
[21] Sabnis GJ，Goloubeva O，Chumsri S，et al. Functional activation of the estrogen receptor alpha and aromatase by the HDAC inhibitor entinostat sensitizes ER negative tumors to letrozole [J]. Cancer Res，2011，71（5）：1893-1903.
[22] Lü M，Ding K，Zhang G，et al. MicroRNA-320a sensitizes tamoxifen-resistant breast cancer cells to tamoxifen by targeting ARPP-19 and ERRγ [J]. Sci Rep，2015，5：8735.
[23] Ikeda K，Horie-Inoue K，Ueno T，et al. miR-378a-3p modulates tamoxifen sensitivity in breast cancer MCF-7 cells through targeting GOLT1A [J]. Sci Rep，2015，5：13170.
[24] Liu J，Li X，Wang M，et al. A miR-26a/E2F7 feedback loop contributes to tamoxifen resistance in ER-positive breast cancer [J]. Int J Oncol，2018，53（4）：1601-1612.
[25] Vilquin P，Donini CF，Villedieu M，et al. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer [J].Breast Cancer Res，2015，17（1）：13.
[26] Masri S，Liu Z，Phung S，et al. The role of microRNA-128a in regulating TGFbeta signaling in letrozole-resistant breast cancer cells [J]. Breast Cancer Res Treat，2010，124（1）：89-99.
[27] Yeo B，Kotsori K，Mohammed K，et al. Long-term outcome of HER2 positive metastatic breast cancer patients treated with frst-line trastuzumab [J]. Breast，2015，24（6）：751-757.
[28] Nahta R，Esteva FJ. Trastuzumab：triumphs and tribulations [J]. Oncogene，2007，26（25）：3637-3643.
[29] Yang F，Fu Z，Yang M，et al. Expression pattern of microRNAs related with response to trastuzumab in breast cancer [J]. J Cell Physiol，2019，234（9）：16102-113.
[30] Nielsen BS，Balslev E，Poulsen TS，et al. miR-21 expression in cancer cells may not predict resistance to adjuvant trastuzumab in primary breast cancer [J]. Frot Oncol，2014，4：207.
[31] De Mattos-Arruda L，Bottai G，Nuciforo PG，et al. MicroRNA-21 links epithelial-to mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients [J]. Oncotarget，2015，6（35）：37269-37280.
[32] Li X，Xu YX，Ding Y，et al. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer [J]. Mol Cancer，2018，17（1）：113.
[33] Lyu H，Huang JC，He Z，et al. Targeting of HER3 with Functional Cooperative miRNAs Enhances Therapeutic Activity in HER2-Overexpressing Breast Cancer Cells [J]. Biol Proced Online，2018，20：16.